Blood test may predict amyloidosis treatment success in days
NCT ID NCT06627309
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether a rapid drop in a blood marker called dFLC can predict a complete response in people with AL amyloidosis treated with daratumumab-based therapy. Researchers will follow 50 patients to see if early changes in dFLC levels match up with later treatment success. The goal is to find a simple way to guide treatment decisions early on.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Daratumumab, bortezomib, and dexamethasone
What this could lead to
If successful, this could help doctors quickly tell if a patient is responding to treatment, allowing for faster adjustments and better outcomes.
What could go wrong
This is a small, early-stage study with only 50 participants. The blood marker may not reliably predict long-term response, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anzhen Hospital
RECRUITINGBeijing, Beijing Municipality, 101118, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chinese PLA Eastern Theater General Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
First Affiliated Hospital of Harbin Medical University
RECRUITINGHarbin, Heilongjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fuxing Hospital affiliated to Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100045, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
-
Shengjing Hospital of China Medical University
RECRUITINGShenyang, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Xi'an Jiao Tong University
RECRUITINGXi'an, China
Contact Phone: •••-•••-•••• Email: •••••@•••••